Farnesyl Transferase Inhibitors as a Novel Strategy for Targeting KRAS-Dependent Cancers

被引：0

作者：

Kargbo, Robert B. ^{[1
]}

机构：

[1] Usona Inst, Fitchburg, WI 53711 USA

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2025年

关键词：

D O I：

10.1021/acsmedchemlett.5c00113

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

KRAS mutations drive tumorigenesis in multiple cancers, yet direct inhibitors display limited efficacy due to adaptive resistance. Recent preclinical findings indicate farnesyl transferase inhibitors (FTIs) can reduce compensatory mTOR and MAPK pathway activation. Evidence supports combining FTIs with KRAS inhibitors to enhance tumor suppression and delayed resistance.

引用

页数：3

共 50 条

[41] Targeting Chemoresistance in Advanced Bladder Cancers with a Novel Adjuvant Strategy
Seremak, Juliette R.
Gupta, Kunj Bihari
Bonigala, Sunilkanth
Liu, Elise
Marshall, Brendan
Zhi, Wenbo
Bokhtia, Riham M.
Panda, Siva S.
Lokeshwar, Vinata B.
Lokeshwar, Bal L.
MOLECULAR CANCER THERAPEUTICS, 2024, 23 (10) : 1389 - 1403
[42] Targeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant miR-193a-3p
Seviour, E. G.
Sehgal, V.
Mishra, D.
Rupaimoole, R.
Rodriguez-Aguayo, C.
Lopez-Berestein, G.
Lee, J-S
Sood, A. K.
Kim, M. P.
Mills, G. B.
Ram, P. T.
ONCOGENE, 2017, 36 (10) : 1339 - 1350
[43] Targeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant miR-193a-3p
E G Seviour
V Sehgal
D Mishra
R Rupaimoole
C Rodriguez-Aguayo
G Lopez-Berestein
J-S Lee
A K Sood
M P Kim
G B Mills
P T Ram
Oncogene, 2017, 36 : 1339 - 1350
[44] Identification of novel farnesyl protein transferase inhibitors using three-dimensional database searching methods.
Kaminski, JJ
Rane, DF
Snow, ME
Weber, L
Rothofsky, ML
Anderson, SD
Lin, SL
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1997, 214 : 193 - MEDI
[45] Novel tricyclic inhibitors of farnesyl protein transferase - Biochemical characterization and inhibition of Ras modification in transfected Cos cells
Bishop, WR
Bond, R
Petrin, J
Wang, L
Patton, R
Doll, R
Njoroge, G
Catino, J
Schwartz, J
Windsor, W
Syto, R
Schwartz, J
Carr, D
James, L
Kirschmeier, P
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (51) : 30611 - 30618
[46] Synthesis and evaluation of a novel series of farnesyl protein transferase inhibitors as non-peptidic CAAX tetrapeptide analogues
Perez, M
Maraval, C
Dumond, S
Lamothe, M
Schambel, P
Etiévant, C
Hill, B
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (08) : 1455 - 1458
[47] Recent progress in targeting KRAS mutant cancers with covalent G12C-specific inhibitors
Rathod, Lala S.
Dabhade, Pratap S.
Mokale, Santosh N.
DRUG DISCOVERY TODAY, 2023, 28 (05) : 1 - 11
[48] Targeting Wnt-driven cancers: Discovery of novel tankyrase inhibitors
Ferri, Martina
Liscio, Paride
Carotti, Andrea
Asciutti, Stefania
Sardella, Roccaldo
Macchiarulo, Antonio
Camaioni, Emidio
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 142 : 506 - 522
[49] Novel natural inhibitors targeting KRAS G12C by computational study
Jiang, Yuting
Chen, Wanting
Wang, Xinhui
Zhou, Baolin
Xie, Haoqun
Hou, Yuanyuan
Guo, Zhen
Yu, Bo
Zhong, Sheng
Su, Xing
ANTI-CANCER DRUGS, 2022, 33 (09) : 779 - 788
[50] Synthesis and biological activity of novel N-cyanoguanidine-halobenzocycloheptapyridine heterocycles as inhibitors of ras farnesyl protein transferase.
Cooper, AB
Wang, J
Desai, JA
Lovey, RG
Doll, RJ
Saksena, AK
Girijavallabhan, V
Ganguly, AK
Bishop, WR
Kirschmeier, P
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1998, 216 : U293 - U293

← 1 2 3 4 5 →